NCT03878849 - Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 15, 2019

Primary Completion Date

March 31, 2027

Study Completion Date

September 30, 2027

Conditions

Advanced Ovarian Cancer

Interventions

DRUG

2X-121

2X-121 will be administered daily as 600 mg (200 mg 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle.

DRUG

2X-121

2X-121 will be administered daily as 800 mg (400 mg (2 x 200 mg) 2X-121 morning dose + 400 mg (2 x 200 mg) 2X-121 evening dose) hard gelatin capsules in a 28 days cycle.

Trial Locations (2)

73104

RECRUITING

OU Health Stephenson Cancer, Oklahoma City

98122

RECRUITING

Swedish Center for Research and Innovation, Seattle